Idience Overview

  • Founded
  • 2019
  • Status
  • Private
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $33.9M
Latest Deal Amount
  • Investors
  • 5

Idience General Information


Developer of oncology drugs intended to deliver breakthroughs that drive innovation and transform cancer treatment. The company's drug is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells, helping cancer patients by targeting multiple solid tumors as monotherapy and for combination with other anti-cancer agents.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 2, Baumoe-ro 27-gil
  • Seocho-gu
  • Seoul, 06752
  • South Korea
+82 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Idience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series B) 01-Oct-2020 $33.9M 000.00 Completed Clinical Trials - Phase 1
To view Idience’s complete valuation and funding history, request access »

Idience Executive Team (5)

Name Title Board Seat Contact Info
Won Lee Chief Executive Officer
Jinsik Suh Chief Financial Officer
Ilkwon Kang Chief Operating Officer
Eun-Jihn Roh Chief Development Officer
Alan Choi Chief Scientific Officer
To view Idience’s complete executive team members history, request access »

Idience Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kiwoom Securities Company Corporation Minority 000 0000 000000 0
Mirae Asset Capital Other Minority 000 0000 000000 0
Seoul Investment Partners Venture Capital Minority 000 0000 000000 0
TS Investment Other Minority 000 0000 000000 0
Yuanta Investment Venture Capital Minority 000 0000 000000 0
To view Idience’s complete investors history, request access »